The best way to reverse a failed clinical trial
All pharmaceutical companies have many drugs that have failed in a previous clinical trial or were not approved by the FDA. Anywhere from $800M to $1.4B and many years have been spent on each compound. What if a percentage of these drugs or their derivatives could be brought to market? Imagine the benefit to patients with novel therapies that previously failed due to underlying genetic variants rendering them susceptible to adverse events. Unlock value from the previous investments straight to the company bottom line.